The evidence-based choice for antipsychotics in children and adolescents should be guaranteed
Drug use in the pediatric population still often features off-label prescriptions, particularly for psychotropic drugs. We reviewed the registration status, scientific evidence, and recommendations from the guidelines for antipsychotics used for psychiatric disorders in children.
Antipsychotic drugs marketed in Italy, the United Kingdom (UK) and United States (US) were identified with the ATC Classification System. The licensing status and Summary of Product Characteristics (SPC) were taken from the national formularies. We analyzed reviews and guidelines on antipsychotics use in children and adolescents in the MEDLINE, EMBASE, and PsycINFO databases.
Out of 67 drugs, 19 were marketed with a pediatric license in at least one country: three in all the selected countries, and only paliperidone with the same indications. Haloperidol was the only antipsychotic authorized for autism in Italy and the UK, and as well as risperidone and aripiprazole in the US. Aripiprazole and paliperidone were licensed in all three countries for schizophrenia. Aripiprazole was licensed for bipolar disorders in all three countries. Haloperidol was licensed for Tourette syndrome in Italy and the UK, and pimozide and aripiprazole in the US.
We retrieved 21 pertinent reviews and 13 guidelines for the management of neuropsychiatric disorders in pediatrics. There was a complete overlap between the authorized therapeutic indications and the available scientific evidence for autism in the US, for conduct disorders and bipolar disorders in the UK, and for Tourette syndrome and tics in the UK and Italy.
These results highlight the different regulatory processes that deny to many children and adolescents the most appropriate and rational antipsychotic therapy.
KeywordsAdolescent Antipsychotic agents Child Mental disorders Off-label drug use
The authors would like to acknowledge Judith Baggott for language editing.
All the authors contributed equally to the design of the study. DP wrote the first draft of the manuscript. AC contributed in writing the manuscript. LR and MB supervised the study. All authors contributed to and have approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.EMA. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for pediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol1/reg_2006_1901/reg_2006_1901_en.pdf (Access 26 Sept 2018).
- 3.European Medicines Agency and its Pediatric Committee. 10-year report to the European Commission general report on the experience acquired as a result of the application of the pediatric Regulation. 27 October 2016 EMA/231225/2015 human medicines Research and Development support division. https://ec.europa.eu/health/sites/health/files/files/paediatricpediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf (Access 26 Sept 2018)
- 9.Ventola CL (2009) Off-label drug information: regulation, distribution, evaluation, and related controversies. PT 34(8):428–440Google Scholar
- 10.General Medical Council (2018) Good practice in prescribing and managing medicines and devices https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/prescribing-and-managing-medicines-and-devices (Access 26 Sept 2018)
- 11.Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21(8):621–645. https://doi.org/10.1016/j.euroneuro.2010.07.002 CrossRefGoogle Scholar
- 12.Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ, Moreno C, Vitiello B, Vorstman J, Zuddas A, European Child and Adolescent Clinical Psychopharmacology Network (2015) Unmet needs in pediatric psychopharmacology: present scenario and future perspectives. Eur Neuropsychopharmacol 25(10):1513–1531. https://doi.org/10.1016/j.euroneuro.2015.06.009 CrossRefGoogle Scholar
- 15.Bujar M, McAuslane N, Walker SR, Salek S (2017) Evaluating quality of decision-making processes in Medicines' development, regulatory review, and health technology assessment: a systematic review of the literature. Front Pharmacol 8:189. https://doi.org/10.3389/fphar.2017.00189 CrossRefGoogle Scholar
- 16.Williamson E, Sathe NA, Andrews JC, Krishnaswami S, McPheeters ML, Fonnesbeck C, Sanders K, Weitlauf A, Warren Z (2017) Medical Therapies for Children With Autism Spectrum Disorder—An Update. Comparative Effectiveness Review No. 189. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290–2015–00003-I.) AHRQ Publication No. 17-EHC009-EF. Rockville, MD: Agency for Healthcare Research and QualityGoogle Scholar
- 17.Pillay J, Boylan K, Carrey N, Newton A, Vandermeer B, Nuspl M, MacGregor T, Ahmed Jafri SH, Featherstone R, Hartling L (2017) First and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update. Comparative Effectiveness Review No. 184. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290–2015–00001-I.) AHRQ Publication No. 17-EHC001-EF. Rockville, MD: Agency for Healthcare Research and Quality. Errata January 2018Google Scholar
- 20.Fung LK, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, Coury D, Whitaker A, Veenstra-Vanderweele J, Hardan AY (2016) Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and Meta-analysis. Pediatrics 137(Suppl 2):S124–S135. https://doi.org/10.1542/peds.2015-2851K CrossRefGoogle Scholar
- 21.Balia C, Carucci S, Coghill D, Zuddas A (2018) The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication? Neurosci Biobehav Rev 91:218–238. https://doi.org/10.1016/j.neubiorev.2017.01.024 CrossRefGoogle Scholar
- 22.Pisano S, Muratori P, Gorga C, Levantini V, Iuliano R, Catone G, Coppola G, Milone A, Masi G (2017) Conduct disorders and psychopathy in children and adolescents: aetiology, clinical presentation and treatment strategies of callous-unemotional traits. Ital J Pediatr 43(1):84. https://doi.org/10.1186/s13052-017-0404-6. CrossRefGoogle Scholar
- 23.Pringsheim T, Hirsch L, Gardner D, Gorman DA (2015) The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers. Can J Psychiatr 60(2):52–61CrossRefGoogle Scholar
- 27.Harvey RC, James AC, Shields GE (2016) A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs 30(1):27–39. https://doi.org/10.1007/s40263-015-0308-1 CrossRefGoogle Scholar
- 28.Pagsberg AK, Tarp S, Glintborg D, Stenstrøm AD, Fink-Jensen A, Correll CU, Christensen R (2017) Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 56(3):191–202. https://doi.org/10.1016/j.jaac.2016.12.013 CrossRefGoogle Scholar
- 29.Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, Leucht S (2018) Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol 28(6):659–674. https://doi.org/10.1016/j.euroneuro.2018.03.008 CrossRefGoogle Scholar
- 31.Meduri M, Gregoraci G, Baglivo V, Balestrieri M, Isola M, Brambilla P (2016) A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies. J Affect Disord 191:187–208. https://doi.org/10.1016/j.jad.2015.11.033 CrossRefGoogle Scholar
- 35.Cox JH, Seri S, Cavanna AE (2016) Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders. Pediatric Health Med Ther 7:57–64. https://doi.org/10.2147/PHMT.S87121.eCollection2016.
- 37.Zhu X, Hu J, Sun B, Deng S, Wen Y, Chen W, Qiu C, Shang D, Zhang M (2018) Comparison of unlicensed and off-label use of antipsychotics prescribed to Child and adolescent psychiatric outpatients for treatment of mental and behavioral disorders with different guidelines: the China Food and Drug Administration versus the FDA. J Child Adolesc Psychopharmacol 28(3):216–224. https://doi.org/10.1089/cap.2017.0079 CrossRefGoogle Scholar
- 39.EMA. SPC Abilify. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000471/WC500020170.pdf (Access 26 Sept 2018).
- 50.Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 13:757–777. https://doi.org/10.2147/TCRM.S117321 CrossRefGoogle Scholar
- 53.Salarvand S, Hemati S, Adibi P, Taleghani F (2018) The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: a review. Oncol Rev 12(2):359. https://doi.org/10.4081/oncol.2018.359.eCollection2018Jul4.